23andMe Holding Co. - Common Stock (ME)
1.9200
+0.1050 (5.79%)
23andMe Holding Co. is a biotechnology company that specializes in personal genomics and biotechnology research
It offers direct-to-consumer genetic testing services, allowing individuals to explore their ancestry, health risks, and genetic traits through easy-to-use saliva collection kits. The company aims to empower people with insights into their genetic information and provide valuable resources for health-related decision-making. Additionally, 23andMe is involved in pharmaceutical research, leveraging its vast genetic database to facilitate drug discovery and development through collaborations with various biopharmaceutical companies.

Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Via Chartmill · March 3, 2025

Tariffs on metal imports create opportunities in ETFs focused on U.S. steelmakers. Top picks are VanEck Steel, SPDR S&P Metals & Mining, and Global X U.S. Infrastructure Development ETF.
Via Benzinga · February 12, 2025

Here's the latest M&A news and auction block updates. Among the most watched items: a TikTok deal is still in flux.
Via Benzinga · January 25, 2025

Via The Motley Fool · December 31, 2024

And cybersecurity consultant Dave Hatter helps us see what's really going on with all of our information.
Via The Motley Fool · December 5, 2024

23andMe restructures, cutting 40% of its workforce and ending its therapeutic programs to save $35 million annually while exploring strategic alternatives.
Via Benzinga · November 12, 2024

We've also got a look at genetic testing company 23andMe .
Via The Motley Fool · October 22, 2024

We're talking tech.
Via The Motley Fool · October 16, 2024

Lawyer raises objections to 23andMe's proposed $30 million settlement, arguing it undermines arbitration rights for 5,000 customers following a data breach. The court is set to review the case in late October.
Via Benzinga · October 2, 2024

Via Benzinga · September 27, 2024

23andMe's independent board members resigned after months of waiting for Anne Wojcicki's fully financed proposal to take the company private.
Via Benzinga · September 18, 2024

Via Benzinga · September 18, 2024

Via Benzinga · August 29, 2024

ME stock results show that 23andMe Holding beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2025.
Via InvestorPlace · August 8, 2024

23andMe stock is up on Friday as investors react to an offer from the company's founder to take it private for 40 cents per share for ME.
Via InvestorPlace · August 2, 2024

Explore personalized nutrition stocks capitalizing on AI, machine learning and genetic profiling to provide targeted dietary solutions.
Via InvestorPlace · July 24, 2024

Hercules Capital, Pfizer and Target offer stability, growth potential and reliable dividends in the realm of high-dividend stocks.
Via InvestorPlace · July 11, 2024

Business development companies can be a lucrative source of passive income.
Via The Motley Fool · June 27, 2024

Don’t miss out on these three penny stocks, which have amazing potential to take off following upcoming business developments this year.
Via InvestorPlace · June 11, 2024

Is altruism a good idea for an unprofitable capitalistic enterprise?
Via The Motley Fool · June 4, 2024

ME stock results show that 23andMe Holding beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2024.
Via InvestorPlace · May 23, 2024